Free Tool — Updated June 2026

Is your compounded GLP-1 actually legal?

Prices swing from $200 to $600 for the same vial, regulations shift by the month, and gray-market sellers look identical to legitimate pharmacies. Pick your medication and where you'd buy it — get an honest read on the legal status, plus exactly what to verify before you commit.

Medication
Where you'd buy it
Your stateoptional

This tool explains the federal compounding framework that governs GLP-1 access. It is educational information, not legal or medical advice.

Legal status
Choose a medication and a source to see where it stands.

The regulatory clock

Compounded GLP-1 legality hinges almost entirely on one federal question: is the brand-name drug in shortage? While a drug is in shortage, pharmacies get wide latitude to compound copies. The moment the FDA declares the shortage resolved, that latitude disappears. Both major GLP-1s are now off the shortage list, and the window for large-scale compounding is closing fast.

What's still legal — and what isn't

Now that the shortages are over, the rules are stricter than most telehealth ads suggest. Here's the honest version:

Still legal: A state-licensed 503A pharmacy can compound a GLP-1 for an individual patient who has a valid prescription and a documented clinical reason the compounded version is needed — a dose that isn't commercially made, or a verified allergy to an inactive ingredient in the FDA-approved product. The federal rules bar compounding something that is "essentially a copy" of an available, approved drug. Critically, "it's cheaper" is not a valid clinical reason on its own.

On borrowed time: 503B outsourcing facilities can still compound from bulk semaglutide and tirzepatide today, but the April 2026 proposal is designed to end exactly that. If your supply comes from a 503B facility, expect it to change.

Not legal for human use: Retatrutide and anything sold as a "research chemical," "not for human consumption," or imported from overseas. Retatrutide isn't FDA-approved at all, so no pharmacy can legally compound it for you. Research-labeled vials sit entirely outside the regulated supply chain — no licensed pharmacist, no prescription, no accountability. For the bigger picture on legality across the whole category, see our guide on whether peptides are legal and how to source peptides safely.

How to vet a compounded GLP-1 provider

A legitimate provider can answer all of these. If you can't confirm them, treat it as a red flag — not a bargain.

Red flags

The price reality

The same compounded vial can cost wildly different amounts depending on the channel — which is exactly why patients end up confused. Rough monthly ranges patients report:

Brand (cash)
$500+
FDA-approved Wegovy, Zepbound, or Ozempic without insurance coverage.
Compounded (legit)
$200–350
A licensed pharmacy with a real prescription and verifiable testing.
Gray market
$50–150
"Research" vials with no pharmacy, no prescription, and no accountability. The savings are the risk.

Price alone tells you very little about legality or safety. A fair price from a verifiable, licensed source is the goal — not the lowest number you can find. To understand what you're actually paying for, our GLP-1 peptides guide breaks down how these medications work.

Free legality alerts

The rules are changing in the next 90 days.

The FDA's bulks-list decision is expected to finalize in Q3 2026. Get a plain-English email the moment compounded GLP-1 legality shifts — so you're never caught buying from a channel that just closed.

No spam. No hype. Just research. Unsubscribe anytime.

More free tools

Reconstitution Calculator Know exactly how many units to draw for your dose. GLP-1 Meal Planner Eat to protect muscle and minimize side effects on GLP-1s. Dosing Converter Convert between mg, mcg, mL, and syringe units instantly. Half-Life Calculator See how a peptide builds up and clears from your system.

Sources

  1. U.S. Food & Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." fda.gov
  2. U.S. Food & Drug Administration. "Declaratory Order: Resolution of Shortages of Tirzepatide Injection." fda.gov
  3. U.S. Food & Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (April 30, 2026). fda.gov
  4. Federal Register. "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B" (May 1, 2026). federalregister.gov
  5. National Community Pharmacists Association. "FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide." ncpa.org

This tool provides general educational information about U.S. drug-compounding regulations and is not legal or medical advice. Laws and FDA policy change frequently and vary by individual circumstance. Verify current status with the FDA, your state board of pharmacy, and a licensed healthcare provider before making any purchasing or treatment decision.